CA
CUE icon

Corriente Advisors’s Cue Biopharma CUE Stock Holding History

Corriente Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-31,613
Closed -$13.8M – 5
2021
Q3 		$13.8M Sell
31,613
-17,953
-36% -$6.26M 26.68% 1
2021
Q2 		$17.3M Sell
49,566
-35,402
-42% -$13.7M 9.34% 2
2021
Q1 		$31.1M Buy
84,968
+21,127
+33% +$8.69M 11.45% 3
2020
Q4 		$24M Buy
63,841
+15,926
+33% +$6.36M 5.7% 7
2020
Q3 		$21.6M Buy
47,915
+25,915
+118% +$14.9M 10.97% 3
2020
Q2 		$16.2M Sell
22,000
-5,333
-20% -$3.86M 10.48% 5
2020
Q1 		$11.6M Buy
27,333
+17,833
+188% +$8.65M 12.56% 4
2019
Q4 		$4.52M Buy
+9,500
New +$2.98M 2.43% 7

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Corriente Advisors's CUE Position: Q4 2021 in Review

Corriente Advisors sold out of Cue Biopharma (CUE) in Q4 2021, closing a stake of 31,613 shares — an estimated $13.8M sold.

Corriente Advisors first reported a position in CUE in Q4 2019 and held it in 8 quarters. The position peaked at $31.1M in Q1 2021. 90 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

  • Corriente Advisors reported no remaining Cue Biopharma position as of Q4 2021 after selling out during the quarter.
  • Corriente Advisors sold 31,613 Cue Biopharma shares in Q4 2021, an estimated $13.8M.
  • Corriente Advisors first reported a position in Cue Biopharma in Q4 2019 and held it in 8 quarters.
  • Corriente Advisors's Cue Biopharma position peaked at $31.1M in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on Corriente Advisors's 13F filing for Q4 2021, filed 15 Feb 2022.